Menu Search
Equities

KALA BIO Inc

27F0:DUS

KALA BIO Inc

Actions
  • Price (EUR)6.11
  • Today's Change0.295 / 5.07%
  • Shares traded-1.00
  • 1 Year change-53.92%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 18:30 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

  • Revenue in USD (TTM)0.00
  • Net income in USD-39.55m
  • Incorporated2009
  • Employees43.00
  • Location
    KALA BIO Inc1167 Massachusetts AvenueARLINGTON 02476United StatesUSA
  • Phone+1 (781) 996-5252
  • Fax+1 (781) 642-0399
  • Websitehttps://www.kalarx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.